Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

• Published in: American journal of physiology: endocrinology and metabolism 2010-12, Vol.299 (6), p.E1076-E1086
• Main Authors: Tatarkiewicz, Krystyna, Smith, Pamela A, Sablan, Emmanuel J, Polizzi, Clara J, Aumann, Donald E, Villescaz, Christiane, Hargrove, Diane M, Gedulin, Bronislava R, Lu, Melissa G W, Adams, Lisa, Whisenant, Tina, Roy, Denis, Parkes, David G
• Format: Article
• Language: English
• Subjects: Analysis of Variance; Animals; Area Under Curve; Cytokines; Cytokines - metabolism; Diabetes; Diabetes Mellitus, Experimental - complications; Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Experimental - pathology; Gene expression; Genes; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Mice; Obesity; Pancreas; Pancreas - drug effects; Pancreas - metabolism; Pancreas - pathology; Pancreatitis - chemically induced; Pancreatitis - complications; Pancreatitis - drug therapy; Pancreatitis - pathology; Peptides - pharmacology; Peptides - therapeutic use; Rats; Rats, Sprague-Dawley; Rodents; Venoms - pharmacology; Venoms - therapeutic use
• ISSN: 0193-1849; 1522-1555
• DOI: 10.1152/ajpendo.00479.2010

The risk of developing pancreatitis is elevated in type 2 diabetes and obesity. Cases of pancreatitis have been reported in type 2 diabetes patients treated with GLP-1 (GLP-1R) receptor agonists. To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents. Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle. Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk. Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured. In ob/ob mice, plasma cytokines (IL-1β, IL-2, IL-6, MCP-1, IFNγ, and TNFα) and pancreatitis-associated genes were assessed. Pancreata were weighed and examined histologically. Exenatide treatment alone did not modify plasma amylase or lipase in any models tested. Exenatide attenuated CRN-induced release of amylase and lipase in normal rats and ob/ob mice but did not modify the response to ST infusion. Plasma cytokines and pancreatic weight were unaffected by exenatide. Exenatide upregulated Reg3b but not Il6, Ccl2, Nfkb1, or Vamp8 expression. Histological analysis revealed that the highest doses of exenatide decreased CRN- or ST-induced acute inflammation, vacuolation, and acinar single cell necrosis in mice and rats, respectively. Ductal cell proliferation rates were low and similar across all groups of ob/ob mice. In conclusion, exenatide did not modify plasma amylase and lipase concentrations in rodents without pancreatitis and improved chemically induced pancreatitis in normal and diabetic rodents.